Falasca, Marco - Curtin University - School of Biomedical Sciences

研究领域

Current specific projects are dedicated to the investigation of the mechanisms involved in development and progression of pancreatic diseases. The main projects investigate the function of phosphoinositides generated through activation of enzymes belonging to the family of PI3Ks, phosphoinositide-dependent kinase-1 (PDK1) and PLC, and signalling pathways activated by Lysophosphatidylinositol

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Falasca, M., and R. Ferro. 2016.“Role of the Lysophosphatidylinositol/GPR55 axis in cancer.”Advances in Biological Regulation 60: 88-93. Chikh, A., R. Ferro, J. Abbott, R. Piñeiro, R. Buus, M. Iezzi, F. Ricci, D. Bergamaschi, P. Ostano, G. Chiorino et al. 2016.“Class II phosphoinositide 3-kinase C2ß regulates a novel signaling pathway involved in breast cancer progression.”Oncotarget 7 (14): 18325-18345. Raimondi, C., V. Calleja, R. Ferro, A. Fantin, A. Riley, B. Potter, C. Brennan, T. Maffucci, B. Larijani, and M. Falasca. 2016.“A Small Molecule Inhibitor of PDK1/PLC?1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion.”Scientific Reports 6: 26142-26142. Mavrommati, I., O. Cisse, M. Falasca, and T. Maffucci. 2016.“Novel roles for class II Phosphoinositide 3-Kinase C2ß in signalling pathways involved in prostate cancer cell invasion.”Scientific Reports 6: 23277-23277. Canobbio, I., L. Cipolla, G. Guidetti, D. Manganaro, C. Visconte, S. Kim, M. Okigaki, M. Falasca, S. Kunapuli, and M. Torti. 2015.“The focal adhesion kinase Pyk2 links Ca²⁺ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets.”Biochemical Journal 469 (2): 199-210. Manganaro, D., A. Consonni, G. Guidetti, I. Canobbio, C. Visconte, S. Kim, M. Okigaki, M. Falasca, E. Hirsch, S. Kunapuli et al. 2015.“Activation of phosphatidylinositol 3-kinase ß by the platelet collagen receptors integrin a2ß1 and GPVI: The role of Pyk2 and c-Cbl.”Biochimica et Biophysica Acta - Molecular Cell Research 1853 (8): 1879-1888. Casari, I., and M. Falasca. 2015.“Diet and Pancreatic Cancer Prevention.”Cancers 7. Sestito, S., G. Nesi, S. Daniele, A. Martelli, M. Digiacomo, A. Borghini, D. Pietra, V. Calderone, A. Lapucci, M. Falasca et al. 2015.“Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.”European Journal of Medicinal Chemistry 105: 274-288. Braccini, L., E. Ciraolo, C. Campa, A. Perino, D. Longo, G. Tibolla, M. Pregnolato, Y. Cao, B. Tassone, F. Damilano et al. 2015.“PI3K-C2? 3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling.”Nature Communications 6: 1-15. Cheung, K., L. Ma, G. Wang, D. Coe, R. Ferro, M. Falasca, C. Buckley, C. Mauro, and F. Marelli-Berg. 2015.“CD31 signals confer immune privilege to the vascular endothelium.”Proceedings of the National Academy of Sciences of USA 112 (43): E5815-E5824. Ruban, E. L., R. Ferro, S. A. Arifin, and M. Falasca. 2014.“Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors.”Biochemical Society. Transactions 42 (5): 1372-1377. Maffucci, T., and M. Falasca. 2014.“New insight into the intracellular roles of class II phosphoinositide 3-kinases.”Biochemical Society. Transactions 42 (5): 1378-1382. Edling, C. E., F. Selvaggi, R. Ghonaim, T. Maffucci, and M. Falasca. 2014.“Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.”Cancer Biology and Therapy 15 (5): 524-532. Franco, I., F. Gulluni, C. C. Campa, C. Costa, J. P. Margaria, E. Ciraolo, M. Martini, D. Monteyne, E. De Luca, G. Germena et al. 2014.“PI3K Class II [alpha] Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function.”Developmental Cell 28 (6): 647-658. Maffucci, T., and M. Falasca. 2014.“Analysis, regulation, and roles of endosomal phosphoinositides.”Methods in Enzymology 535: 75-91. Nesi, G., S. Sestito, V. Mey, S. Ricciardi, M. Falasca, R. Danesi, A. Lapucci, M. Breschi, S. Fogli, and S. Rapposelli. 2013.“Synthesis of novel 3,5-disubstituted-2-oxindole derivatives as antitumor agents against human nonsmall cell lung cancer.”ACS Medicinal Chemistry Letters 4 (12): 1137-1141. Canobbio, I., L. Cipolla, A. Consonni, S. Momi, G. Guidetti, B. Oliviero, M. Falasca, M. Okigaki, C. Balduini, P. Gresele et al. 2013.“Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2.”Blood 121 (4): 648-657. Fyffe, C., and M. Falasca. 2013.“3-phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.”Cancer Management and Research 5 (1): 271-280. Lattanzio, R., M. Marchisio, R. La Sorda, N. Tinari, M. Falasca, S. Alberti, S. Miscia, C. Ercolani, A. Di Benedetto, L. Perracchio et al. 2013.“Overexpression of activated phospholipase C?1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.”International Journal of Cancer 132 (5): 1022-1031. Cipolla, L., A. Consonni, G. Guidetti, I. Canobbio, M. Okigaki, M. Falasca, E. Ciraolo, E. Hirsch, C. Balduini, and M. Torti. 2013.“The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling.”Journal of Thrombosis and Haemostasis 11 (2): 345-356.